Aravive 003: AVB-S6-500 A phase 1b/2 study of AVB-S6-500 in combination with cabozantinib, AVB-S6-500 in combination with cabozantinib and nivolumab, and AVB-S6-500 monotherapy in patients with advanced of metastatic clear cell renal cell carcinoma

Administered By

Awarded By

Contributors

Start/End

  • April 11, 2022 - April 13, 2027